Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectinsP J Giannasca
OraVax, Inc, Cambridge, Massachusetts 02139, USA
Infect Immun 65:4288-98. 1997
..The selective recognition of NALT M cells by a lectin in vivo provides a model for microbial adhesin-host cell receptor interactions on M cells and the targeted delivery of immunogens to NALT following intranasal administration...
- A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys
F Guirakhoo
Acambis, Inc, 38 Sidney St, Cambridge, MA 02139, USA
J Virol 78:9998-10008. 2004
..These changes may be responsible for virus attenuation through a change in the pH threshold for virus envelope fusion with the host cell membrane...
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human prT P Monath
OraVax Inc, Cambridge, MA 02139, USA
Vaccine 17:1869-82. 1999
....
- Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys
T P Monath
OraVax Inc, Cambridge, Massachusetts 02139, USA
J Virol 74:1742-51. 2000
..ChimeriVax-JE meets preclinical safety and efficacy requirements for a human vaccine; it appears safer than yellow fever 17D vaccine but has a similar profile of immunogenicity and protective efficacy...
- Ecology of Marburg and Ebola viruses: speculations and directions for future research
T P Monath
Research and Medical Affairs, OraVax, Inc, Cambridge Massachusetts 02139, USA
J Infect Dis 179:S127-38. 1999
..Such viruses may have separate life cycles or may give rise to virulent strains by mutation...
- Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis
F Guirakhoo
OraVax, Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
Virology 257:363-72. 1999
..All attenuating residues and the avirulent phenotype were preserved after 18 passages in cell cultures or 6 passages in mouse brains...
- Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates
F Guirakhoo
OraVax, Inc, Cambridge, Massachusetts 02139, USA
J Virol 74:5477-85. 2000
..The high replication efficiency, attenuation phenotype in mice and monkeys, immunogenicity and protective efficacy, and genomic stability of ChimeriVax-D2 justify it as a novel vaccine candidate to be evaluated in humans...
- Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys
C K Lee
OraVax, Inc, Cambridge, MA, USA
Vaccine 17:1493-505. 1999
..This study provides the first evidence for effective vaccination of nonhuman primates against H. pylori, and preliminary evidence that a reduction in bacterial density attributable to immunization may lessen gastric inflammation...
- Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection
H Kleanthous
OraVax, Inc, Cambridge, Massachusetts 02139, USA
Infect Immun 66:2879-86. 1998
..pylori and equivalent for all routes. These results identify both the rectum and nasal passages as suitable inductive sites for urease immunization...
- Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection
G A Myers
OraVax Inc, Cambridge, MA 02139, USA
Vaccine 17:1394-403. 1999
..This study shows that immunization with rUre plus LT results in long-lasting protective immunity against challenge with H. felis...
- Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine
F Guirakhoo
Acambis, Inc, Cambridge, Massachusetts 02139, USA
J Virol 75:7290-304. 2001
..However, preimmune monkeys developed either no detectable viremia or a level of viremia lower than that in nonimmune controls. This is the first recombinant tetravalent dengue vaccine successfully evaluated in nonhuman primates...
- Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)
J Arroyo
OraVax, Inc, Cambridge, Massachusetts 02139, USA
J Virol 75:934-42. 2001
....
- Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates
F Guirakhoo
Acambis Inc, Cambridge, Massachusetts 02139, USA
Virology 298:146-59. 2002
..This indicates that further formulations for dose adjustments need to be tested in monkeys to identify an optimal formulation for humans...
- Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori
C K Lee
OraVax Inc, Cambridge, MA 02139, USA
Vaccine 17:3072-82. 1999
..However, monkeys receiving the two parenteral-only regimens had slightly elevated gastritis scores...
- Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent
H Kleanthous
Acambis, Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Vaccine 19:4883-95. 2001
..These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity...
- Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection
R Weltzin
OraVax, Inc, Cambridge, Massachusetts 02139, USA
Infect Immun 68:2775-82. 2000
..These results show that LT and LTB stimulate qualitatively different humoral immune responses to urease but are both effective parenteral adjuvants for immunization of mice against H. pylori infection...
- Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters
P J Giannasca
OraVax, Inc, Cambridge, Massachusetts 02139, USA
Infect Immun 67:527-38. 1999
..These results suggest that prophylactic parenteral vaccination or intravenous immunotherapy could provide protection from C. difficile disease in humans...
- Yellow fever vector live-virus vaccines: West Nile virus vaccine development
J Arroyo
Acambis Inc 38 Sidney Street, Cambridge, MA 02319, USA
Trends Mol Med 7:350-4. 2001
....
- Prospects for development of a vaccine against the West Nile virus
T P Monath
Research and Medical Affairs, Acambis Incorporated, Cambridge, Massachusetts 02139, USA
Ann N Y Acad Sci 951:1-12. 2001
..The chimeric virus replicates in the host like yellow fever 17D but immunizes specifically against West Nile virus...
- West Nile virus vaccine
T P Monath
Acambis Inc, 38 Sidney Street, Cambridge, Massachusetts 02139, USA
Curr Drug Targets Infect Disord 1:37-50. 2001
....
- Japanese encephalitis vaccines: current vaccines and future prospects
T P Monath
Acambis Inc, 38 Sidney Street, Cambridge, MA 02139, USA
Curr Top Microbiol Immunol 267:105-38. 2002
..Other approaches to JE vaccines--including naked DNA, oral vaccination, and recombinant subunit vaccines--have been reviewed...
- Yellow fever: an update
T P Monath
Acambis Inc, Cambridge, Massachusetts 02139, USA
Lancet Infect Dis 1:11-20. 2001
..New applications of yellow fever 17D virus as a vector for foreign genes hold considerable promise as a means of developing new vaccines against other viruses, and possibly against cancers...
- Intranasal antibody prophylaxis for protection against viral disease
R Weltzin
OraVax, Inc, Cambridge, Massachusetts 02139, USA
Clin Microbiol Rev 12:383-93. 1999
..Polyclonal human immunoglobulin from pooled plasma preparations can be used to provide broad protection against a number of different pathogens, while monoclonal antibodies or their fragments can be used to target specific viruses...
- Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses
T H Ermak
OraVax, Inc, Cambridge, Massachusetts 02139
J Exp Med 188:2277-88. 1998
..pylori infection by immunization with the urease antigen is dependent on MHC class II-restricted, cell-mediated mechanisms, and antibody responses to urease are not required for protection...
